In addition, silencing or inhibiting FGFR4 in patients with CRC has been observed to make cancer cells more sensitive to two types of treatments against CRC: 5-FU (5-fluorouracil) and oxaliplatin [49]. Here, FGFR4 is linked to colorectal carcinoma.